Repligen (NASDAQ:RGEN) Shares Down 4.8% – Here’s What Happened

Repligen Co. (NASDAQ:RGEN) traded down 4.8% on Friday . The stock traded as low as $133.33 and last traded at $135.54. 23,261 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 657,365 shares. The stock had previously closed at $142.43.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Wolfe Research started coverage on Repligen in a research note on Thursday. They issued a “peer perform” rating for the company. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Trading Down 11.4 %

The stock has a market cap of $7.07 billion, a PE ratio of -361.50, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96. The company has a 50 day moving average of $141.59 and a two-hundred day moving average of $144.78. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 EPS. Sell-side analysts anticipate that Repligen Co. will post 1.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. Andra AP fonden acquired a new stake in shares of Repligen in the second quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in shares of Repligen in the 2nd quarter worth $33,000. UMB Bank n.a. raised its holdings in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the period. Lazard Asset Management LLC raised its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.